Synchronous presentation of hepatoid alpha-fetoprotein-producing lung cancer and colorectal adenocarcinoma

Francesco Valentino, Martina Torchio, Patrizia Morbini, Marco Danova

Research output: Contribution to journalArticlepeer-review


We describe the synchronous presentation of hepatoid adenocarcinoma of the lung and colorectal adenocarcinoma in a patient with elevated alpha-fetoprotein (AFP) serum levels. Our patient was treated after surgery with a conventional chemotherapy regimen including bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, which was demonstrated to improve the clinical results in the treatment of colorectal and lung cancer compared with chemotherapy alone, and is today approved both for colon and lung cancer. Besides the unconventional association of the two cancer types in our patient and the unsatisfactory clinical benefit obtained with the medical treatment administered, we report on the significance of AFP serum levels as a tumor marker in this peculiar situation. In our patient these levels, monitored from the first clinical symptoms through the last chemotherapy course, did not show any correlation with the response to treatment or with the patient's overall outcome. In particular, the serum marker remained essentially unchanged after the surgical removal of the lung mass and the subsequent chemotherapy.

Original languageEnglish
Issue number5
Publication statusPublished - Sep 2012


  • Alpha-fetoprotein
  • Colon adenocarcinoma
  • Hepatoid differentiation
  • Lung adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Synchronous presentation of hepatoid alpha-fetoprotein-producing lung cancer and colorectal adenocarcinoma'. Together they form a unique fingerprint.

Cite this